Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Botha

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Intensive Care Medicine|May 1, 1996
Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patientF J Botha, P van der Bijl, H I Seifart, et al.
Pharmacoepidemiology and Drug Safety|August 14, 2001
Population screening for isoniazid acetylator phenotypeH I Seifart, D P Parkin, F J Botha, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|February 1, 1996
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosisF J Botha, F A Sirgel, D P Parkin, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosisF A Sirgel, F J Botha, D P Parkin, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 1993
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessmentF A Sirgel, F J Botha, D P Parkin, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosisP R Donald, F A Sirgel, F J Botha, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 1997
Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosisD P Parkin, S Vandenplas, F J Botha, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2000
Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosisP R Donald, F A Sirgel, T P Kanyok, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Intensive Care Medicine|May 1, 1996
Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patientF J Botha, P van der Bijl, H I Seifart, et al.
Pharmacoepidemiology and Drug Safety|August 14, 2001
Population screening for isoniazid acetylator phenotypeH I Seifart, D P Parkin, F J Botha, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|February 1, 1996
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosisF J Botha, F A Sirgel, D P Parkin, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosisF A Sirgel, F J Botha, D P Parkin, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 1993
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessmentF A Sirgel, F J Botha, D P Parkin, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosisP R Donald, F A Sirgel, F J Botha, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 1997
Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosisD P Parkin, S Vandenplas, F J Botha, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2000
Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosisP R Donald, F A Sirgel, T P Kanyok, et al.
Pageof 1